2023
Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease
Siegel S, Griffith D, Philley J, Brown-Elliott B, Brunton A, Sullivan P, Fuss C, Strnad L, Wallace R, Winthrop K. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. CHEST Journal 2023, 164: 846-859. PMID: 37419144, PMCID: PMC10645596, DOI: 10.1016/j.chest.2023.05.036.Peer-Reviewed Original ResearchConceptsAmikacin liposome inhalation suspensionAmikacin resistanceCulture conversionInhalation suspensionMycobacterium abscessus lung diseasePresence of macrolide resistanceEnd pointsMicrobiological end pointsMonthly sputum culturesSputum culture conversionTreatment-refractory diseaseOpen-label protocolSecondary end pointsOpen-label trialCohort of patientsCavitary diseaseSputum culturePretreatment isolatesM abscessusOpen-labelOral antimicrobialsParenteral antibioticsCompanion therapyMacrolide resistanceMultidrug therapy
2020
Evaluation of Antimicrobial Susceptibility to Amikacin Liposome Inhalation Suspension and Relapse/Reinfection in Pulmonary M. Abscessus Disease
Siegel S, Brown-Elliott B, Strnad L, Fuss C, Griffith D, Wallace, Jr. R, Philley J, Winthrop K. Evaluation of Antimicrobial Susceptibility to Amikacin Liposome Inhalation Suspension and Relapse/Reinfection in Pulmonary M. Abscessus Disease. 2020, a4495-a4495. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4495.Peer-Reviewed Original Research